A blended digital and face-to-face reasoning intervention for paranoia. Its 2021 trial did not establish a significant benefit on the prespecified total paranoia score at 24 weeks, despite favourable secondary results. This illustrates why endpoint, timing and process engagement matter when evaluating innovation.[ref]
Effects of SlowMo, a Blended Digital Therapy Targeting Reasoning, on Paranoia Among People With Psychosis: A Randomized Clinical Trial by Philippa Garety and others. JAMA Psychiatry 78, 714–725; 361 in analysis, prespecified 24-week GPTS total endpoint and secondary outcomes
New to topics? Read the docs here!